RIGL
Rigel Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RIGL
Rigel Pharmaceuticals, Inc.
A biotech company that developing novel small molecule drugs for hematologic disorders, cancer, and rare immune diseases
611 Gateway Boulevard, Suite 900, South San Francisco, California 94080
--
Rigel Pharmaceuticals, Inc., was founded in Delaware on June 14, 1996. The company is a biotechnology company dedicated to discovering, developing and delivering new therapies that significantly improve the lives of patients with hematological diseases and cancer. The Company's first FDA-approved product is TAVALISSE (disodium hexahydrate fortamatinib) tablets, the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatment. The company's second FDA-approved product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible isocitrate dehydrogenase 1 (IDH) mutations detected in FDA-approved trials.
Earnings Call
Q1/2025
Estimate EPS0.09
Actual EPS0.63
Estimate Revenue43.87M
Actual Revenue53.33M
Rigel Pharmaceuticals' 2025 Q1 Earnings: Unpacking Contradictions in Market Dynamics and Growth Projections
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.4
Actual EPS3.28
Estimate Revenue72.58M
Actual Revenue101.69M
Rigel Pharmaceuticals' Q2 2025: Unpacking Contradictions in Tavalisse Growth and GAVRETO Sales Dynamics
Aug 05,2025 08:14
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RIGL has released its 2025 Q3 earnings. EPS was reported at 1.46, versus the expected 0.94, beating expectations. The chart below visualizes how RIGL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RIGL has released its 2025 Q3 earnings report, with revenue of 69.46M, reflecting a YoY change of 25.59%, and net profit of 27.90M, showing a YoY change of 124.62%. The Sankey diagram below clearly presents RIGL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
